Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer

Annals of Internal Medicine

Volumn 154, Issue 1, 2011, Pages 37-49

  Dahabreh, Issa J ^a   Terasawa, Teruhiko ^a   Castaldi, Peter J ^a   Trikalinos, Thomas A ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b Fujita Health University Fujita Health University Nanakuri Memorial Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; GENE MUTATION; HAZARD RATIO; HUMAN; META ANALYSIS (TOPIC); METASTASIS; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; WILD TYPE;

EID: 79551580551     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-154-1-201101040-00006     Document Type: Review

References (93)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49. [PMID: 19474385]
2. Alberts SR, Wagman LD. Chemotherapy for colorectal cancer liver metasta-ses. Oncologist. 2008;13:1063-73. [PMID: 18838438]
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375:1030-47. [PMID: 20304247]
4. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science. 2002;297:63-4. [PMID: 12098689]
5. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15:699-731. [PMID: 20584808]
6. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7 Suppl 4:2-8. [PMID: 12202782]
7. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4:361-70. [PMID: 15122207]
8. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16:102-8. [PMID: 15598946]
9. Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M, Danenberg KD, et al. Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases. Cancer Chemother Pharmacol. 2010;65:825-31. [PMID: 19701635]
10. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357: 2040-8. [PMID: 18003960]
11. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory meta-static colorectal cancer. J Clin Oncol. 2007;25:1658-64. [PMID: 17470858]
12. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49: 4682-9. [PMID: 2547513]
13. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Bi-omarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101: 1308-24. [PMID: 19738166]
14. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with met-astatic colorectal cancer. J Clin Oncol. 2008;26:1626-34. [PMID: 18316791]
15. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Teb-butt NC, et al. K-ras mutations and benefit from cetuximab in advanced colo-rectal cancer. N Engl J Med. 2008;359:1757-65. [PMID: 18946061]
16. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colo-rectal cancer. N Engl J Med. 2009;360:1408-17. [PMID: 19339720]
17. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetux-imab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-71. [PMID: 19114683]
18. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446-52. [PMID: 19815849]
19. Lin BK, Clyne M, Walsh M, Gomez O, Yu W, Gwinn M, et al. Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Am J Epidemiol. 2006;164:1-4. [PMID: 16641305]
20. Savas S, Younghusband HB. dbCPCO: a database of genetic markers tested for their predictive and prognostic value in colorectal cancer. Hum Mutat. 2010; 31:901-7. [PMID: 20506273]
21. Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, et al. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol. 2007;25:3572-5. [PMID: 17704403]
22. Mayer RJ. Targeted therapy for advanced colorectal cancer-more is not always better [Editorial]. N Engl J Med. 2009;360:623-5. [PMID: 19196680]
23. Senn SJ. Overstating the evidence: double counting in meta-analysis and related problems. BMC Med Res Methodol. 2009;9:10. [PMID: 19216779]
24. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17:2815-34. [PMID: 9921604]
25. Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care. 2005;21:119-25. [PMID: 15736523]
26. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8: 16. [PMID: 17555582]
27. Rothman KJ, Greenland S, Lash TJ. Modern Epidemiology. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1997.
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-4. [PMID: 16106022]
29. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. [PMID: 12543843]
30. Irwig L, Tosteson AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994; 120:667-76. [PMID: 8135452]
31. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM; Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889-97. [PMID: 19075208]
32. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kos-midis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962-72. [PMID: 18804418]
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
34. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
35. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101. [PMID: 7786990]
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34. [PMID: 9310563]
37. Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol. 2005; 58:894-901. [PMID: 16085192]
38. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006;333:597-600. [PMID: 16974018]
39. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58:982-90. [PMID: 16168343]
40. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach [Letter]. J Clin Epidemiol. 2006;59:1331-2; author reply 1332-3. [PMID: 17098577]
41. Harbord RM, Whiting P. metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata Journal. 2009;9:211-29.
42. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22:2693-710. [PMID: 12939780]
43. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559-73. [PMID: 12111920]
44. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589-624. [PMID: 11836738]
45. Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Meth-odol. 2009;9:80. [PMID: 19961608]
46. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-80. [PMID: 19114685]
47. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563-72. [PMID: 19196673]
48. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hart-mann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol. 2010;11:38-47. [PMID: 19942479]
49. Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2009;15:4508-13. [PMID: 19549774]
50. Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Mar-tinelli E, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol. 2010;21:1537-45. [PMID: 19940007]
51. Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg. 2010;251:254-60. [PMID: 20010090]
52. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279-86. [PMID: 15863375]
53. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-5. [PMID: 16618717]
54. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643-8. [PMID: 17363584]
55. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96:1166-9. [PMID: 17375050]
56. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007;97:1139-45. [PMID: 17940504]
57. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-7. [PMID: 17664471]
58. Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008;99:83-9. [PMID: 18577988]
59. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508-15. [PMID: 17998284]
60. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-12. [PMID: 19001320]
61. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008;7:184-90. [PMID: 18621636]
62. Goncalves A, Esteyries S, Taylor-Smedra B, Lagarde A, Ayadi M, Monges G, et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer. 2008;8:169. [PMID: 18544172]
63. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-9. [PMID: 18202412]
64. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008; 14:7884-95. [PMID: 19047118]
65. Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res. 2008;14:5869-76. [PMID: 18794099]
66. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of FcyRIIa-FcyRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009;27:1122-9. [PMID: 19164213]
67. Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Cruger D, et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol. 2009;20:879-84. [PMID: 19179548]
68. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009;27:5068-74. [PMID: 19738126]
69. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27: 5924-30. [PMID: 19884556]
70. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009;27:2622-9. [PMID: 19398573]
71. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101:715-21. [PMID: 19603018]
72. Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer. 2009;100:1087-94. [PMID: 19293803]
73. Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2009;39:321-6. [PMID: 19287023]
74. Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer. 2009;100: 1330-5. [PMID: 19367287]
75. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009;20:84-90. [PMID: 18669866]
76. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009;15:3184-8. [PMID: 19366826]
77. Paule B, Castagne V, Picard V, Saffroy R, Adam R, Guettier C, et al. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol. 2009. [PMID: 19862647]
78. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851-7. [PMID: 19223544]
79. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009;4:e7287. [PMID: 19806185]
80. Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, et al. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. Oncology. 2009;77:224-30. [PMID: 19738388]
81. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009;101:465-72. [PMID: 19603024]
82. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010;19:358-65. [PMID: 20086114]
83. Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. 2010;10:458-64. [PMID: 20177422]
84. Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, et al. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Br J Cancer. 2010;102:1137-44. [PMID: 20234366]
85. Perkins G, Lievre A, Ramacci C, Méatchi T, de Reynies A, Emile JF, et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer. 2010;127:1321-31. [PMID: 20049837]
86. Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zani-boni A, et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer. 2010;127:1941-7. [PMID: 20099280]
87. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-6. [PMID: 19188670]
88. Simon R. Clinical trials for predictive medicine: new challenges and paradigms. Clin Trials. 2010;7:516-24. [PMID: 20338899]
89. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, et al; Cancer and Leukemia Group B. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15:7322-9. [PMID: 19934290]
90. Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, et al. Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis. 2004;19:23-42. [PMID: 12827409]
91. U.S. Food and Drug Administration. Panitumumab: highlights of prescribing information. 2009. Accessed at www.accessdata.fda.gov/drugsatfda_docs/label/2009/125147s080lbl.pdf on 22 September 2010.
92. Hebbar M, Fournier P, Romano O. KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear? Eur J Cancer Care (Engl). 2010;19:167-71. [PMID: 19702696]
93. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027-34. [PMID: 19597023]